RealFeedApp Ribupatide studied in more than 20 clinical trials
The company will showcase results from KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3 trials, alongside an analysis of unmet clinical needs for adults with class II and III obesity.
- Field
- drugs and trials
- What they did
- Kailera Therapeutics will present clinical and real-world research on its obesity treatment trials at ObesityWeek 2026, including Phase 3 trials KaiNETIC-1, -2, and -3.
- Why it matters
- This presentation will help researchers and clinicians better understand the efficacy of new oral and injectable GLP-1 and GLP-1/GIP agonist drugs, such as safiglipron and ribupatide, for adults with obesity.
#obesity#clinical trial#phase 3#glp-1#kailera
